StreetInsider.com News Articles

Champions Oncology to present research findings at AACR 2026 conference

Thu, 09 Apr 2026 13:40:12 -0400

Champions Oncology, Inc. (NASDAQ: CSBR) announced it will present eight poster presentations at the American Association for Cancer Research Annual Meeting from April 17-22, 2026, in San Diego, California.

The presentations will cover research on KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates, and CAR-T therapies. The studies utilize patient-derived models combined with molecular, functional, and phenotypic data.

The company stated the research demonstrates approaches for predicting therapeutic response and resistance in oncology drug development. The data aims to show how preclinical models can help identify biomarkers and inform development decisions.

"At AACR 2026, we are presenting data that directly address one of

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Thu, 09 Apr 2026 13:40:00 -0400

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions

HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California.

The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals,

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Thu, 09 Apr 2026 13:40:00 -0400

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions

The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals,

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Mar 24

Mon, 30 Mar 2026 13:16:00 -0400

si-local-file:///var/storage/secattach/20260330/26239794.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Mar 24

Mon, 30 Mar 2026 13:16:00 -0400

si-local-file:///var/storage/secattach/20260330/26239794.html

Champions Oncology appoints Brian Alexander to board of directors

Mon, 30 Mar 2026 10:55:11 -0400

Champions Oncology, Inc. (NASDAQ: CSBR) announced the appointment of Brian Alexander, MD, MPH, to its board of directors. Alexander previously held senior leadership positions at Valo Health, Flagship Pioneering, and Foundation Medicine.

The translational oncology research organization stated the appointment supports its strategy to expand the use of clinically relevant data in drug discovery and development. Champions operates a portfolio of patient-derived tumor models combined with molecular and clinical datasets.

"Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris, chairman of the board at Champions Oncology.

Alexander commented on

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Mon, 30 Mar 2026 10:55:00 -0400

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D

HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Mon, 30 Mar 2026 10:55:00 -0400

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D

Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Jan 31

Thu, 12 Mar 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260312/26154225.html

Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Jan 31

Thu, 12 Mar 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260312/26154225.html

Champions Oncology (CSBR) Misses Q3 EPS by 4c

Thu, 12 Mar 2026 16:28:22 -0400

Champions Oncology (NASDAQ: CSBR) reported Q3 EPS of $0.04, $0.04 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $16.6 million versus the consensus estimate of $16.43 million.

For earnings history and earnings-related data on Champions Oncology (CSBR) click here.

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Mar 12

Thu, 12 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260312/26153433.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Mar 12

Thu, 12 Mar 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260312/26153433.html

Champions Oncology reports Q3 revenue of $16.6 million

Thu, 12 Mar 2026 16:02:06 -0400

Champions Oncology Inc. (NASDAQ: CSBR) reported total revenue of $16.6 million for its third quarter of fiscal 2026, ended January 31, 2026, according to a company statement. This represents a 2.8% decrease from $17.0 million in the same period last year.

The translational oncology research organization achieved record study service revenue of $16.6 million, marking a 32% increase year-over-year. The decline in total revenue was attributed to the absence of a $4.5 million data license transaction that was recognized in the third quarter of fiscal 2025.

The company reported a net loss of $279,000 for the quarter, compared to net income of

Champions Oncology Reports Revenue of $16.6 Million

Thu, 12 Mar 2026 16:01:00 -0400

Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year

HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026.

Third Quarter and Recent Highlights:

Record study service revenue of $16.6 million, up approximately 32% year over year
Total revenue of $16.6 million, compared to $17.0 million in the prior-year period
Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000

The Company's third

Champions Oncology Reports Revenue of $16.6 Million

Thu, 12 Mar 2026 16:01:00 -0400

Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year

Third Quarter and Recent Highlights:

Record study service revenue of $16.6 million, up approximately 32% year over year
Total revenue of $16.6 million, compared to $17.0 million in the prior-year period
Adjusted EBITDA of $574,000; GAAP loss from operations of approximately $276,000

The Company's third

Form 4 CHAMPIONS ONCOLOGY, INC. For: Jul 16 Filed by: Brainin Robert Lawrence

Fri, 30 Jan 2026 15:56:00 -0400

si-local-file:///var/storage/secattach/20260130/25923313.html

Form 4 CHAMPIONS ONCOLOGY, INC. For: Jul 16 Filed by: Brainin Robert Lawrence

Fri, 30 Jan 2026 15:56:00 -0400

si-local-file:///var/storage/secattach/20260130/25923313.html

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 05 Filed by: Brainin Robert Lawrence

Fri, 30 Jan 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260130/25921636.html

Form 4 CHAMPIONS ONCOLOGY, INC. For: Nov 05 Filed by: Brainin Robert Lawrence

Fri, 30 Jan 2026 12:16:00 -0400

si-local-file:///var/storage/secattach/20260130/25921636.html

Form 3 CHAMPIONS ONCOLOGY, INC. For: Jun 09 Filed by: Brainin Robert Lawrence

Fri, 16 Jan 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260116/25860945.html

Form 3 CHAMPIONS ONCOLOGY, INC. For: Jun 09 Filed by: Brainin Robert Lawrence

Fri, 16 Jan 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260116/25860945.html

Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Oct 31

Mon, 15 Dec 2025 16:59:00 -0400

si-local-file:///var/storage/secattach/20251215/25741514.html

Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Oct 31

Mon, 15 Dec 2025 16:59:00 -0400

si-local-file:///var/storage/secattach/20251215/25741514.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Dec 15

Mon, 15 Dec 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20251215/25740864.html